What is the current role for genetic profile testing (e.g. DecisionDx-SCC) in the treatment paradigm for cutaneous malignancies?
Have you utilized these gene-expression profiles in your practice?
Is there sufficient data for this test to be used for clinical decisions?
Community PollStarted
What is the current role for genetic profile testing (e.g. DecisionDx-SCC) in the treatment paradigm for cutaneous malignancies?
56 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet Member
Radiation Oncology · Cleveland Clinic
Answered on
This is a very cool test that has a lot of potential to help us make decisions in practice (full disclosure, I advise Castle and get research support from them, but am not directly compensated by them). The data published thus far shows that it is prognostic to predict nodal or distant mets. However...
Join for free or sign in to see the full answer
Mednet Member
Radiation Oncology · University of New Mexico Comprehensive Cancer Center
Answered on
Currently, the DecisionDx-SCC is best understood as prognostic but not predictive. This means that there is a lot of data supporting a correlation between the test score and the risk of metastases (mainly nodal). Some of this data can be found in the following publications:
Join for free or sign in to see the full answer